Table 1. Clinical and pathological features of the human prostate cancer data sets.
The table describes the characteristics of the samples within the given data sets that were actually used in the study (see table S2).
| Name and purpose | Yu et al. training set | Taylor et al. test set | Sboner et al. training set | Sboner et al. test set | HICCC TMA | Biopsy cohort |
|---|---|---|---|---|---|---|
| Description of samples analyzed in this study | 29 aggressive 58 adjacent normal primary tumors |
131 tumors 23 adjacent normal primary tumors |
25 indolent 29 lethal TURP |
28 indolent 8 lethal TURP |
44 tumors 102 adjacent normal primary tumors |
29 nonfailed 14 failed biopsies |
| Median age (years ± MAD) | NA | 57.1 ± 4.3 | 71.5 ± 2.5 | 76.5 ± 7 | 59 ± 3 | 69.4 ± 7.3 |
| Pretreatment PSA (ng/ml ± SD) | NA | 8.6 ± 8.1 | NA | NA | 9 ± 6.7 | 6.1 ± 5.6 |
| Pathology stage T | ||||||
| T2 | 7 | 85 | 23 | |||
| T3 | 20 | 39 | NA | NA | 17 | NA |
| T4 | 2 | 4 | 4 | |||
| Clinical T stage | ||||||
| T1 | 75 | 39 | ||||
| T2 | NA | 51 | NA | NA | 4 | |
| T3 | 5 | NA | 0 | |||
| Pathology stage N | ||||||
| N0 | 102 | 40 | ||||
| N1 | NA | 6 | NA | NA | 1 | NA |
| Nx | 23 | 3 | ||||
| Pathology Gleason score | ||||||
| ≤5 | 2 | 0 | 0 | |||
| 6 | 4 | 41 | NA | NA | 20 | NA |
| 7 | 10 | 54 (3 + 4) 20 (4 + 3) |
24 (3 + 4) | |||
| ≥8 | 13 | 15 | ||||
| Biopsy Gleason score | ||||||
| ≤5 | 1 | 0 | 0 | 0 | ||
| 6 | NA | 77 | 18 | 19 | NA | 43 |
| 7 | 29 (3 + 4) 13 (4 + 3) |
11 (3 + 4) 5 (4 + 3) |
17 (3 + 4) 0 (4 + 3) |
0 | ||
| ≥8 | 11 | 20 | 0 | 0 | ||
| SVI (%) | ||||||
| Negative | NA | 89.3 | NA | NA | NA | |
| Positive | 10.8 | NA | ||||
| Extracapsular extension (%) | ||||||
| Present | NA | 67.7 | NA | NA | NA | |
| Absent | 32.3 | NA | ||||
| BCR median (months ± MAD) | NA | 17.8 ± 10.6 | NA | NA | 42 ± 30 | NA |
| Median overall survival (months ± MAD) | NA | NA | 33 ± 5 | 43.5 ± 0.5 | NA | NA |
HICCC, Herbert Irving Comprehensive Cancer Center; MAD, median absolute deviation; NA, information was either not available or not applicable; SVI, seminal vesicle involvement; TURP, transurethral resection of prostate.